Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Gynecology

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 46 articles: HTML format

Single Articles

May 2025
1. KIM N, Kim YN, Lee K, Park E, et al
   Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma.
   Clin Cancer Res. 2025 May 13. doi: 10.1158/1078-0432.CCR-24-4263.
   PubMed     Abstract available
   
   
   
2. CHUI MH, Kang EY, Kahn RM, Chiang S, et al
   Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-Grade Serous Tumors with Histologic Transformation.
   Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-3168.
   PubMed     Abstract available
   
   
   April 2025
3. KAAKS R, Cooley V, Mukama T, Teras LR, et al
   A Prospective Study Consortium for the Discovery and Validation of Early Detection Markers for Ovarian Cancer ("PREDICT") - Baseline findings for CA125.
   Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1845.
   PubMed     Abstract available
   
   
   
4. LEE JM, Miller A, Rose PG, AlHilli M, et al
   Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial.
   Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3877.
   PubMed     Abstract available
   
   
   March 2025
5. COSCIA F, Nielsen AB, Weigert M, Watters K, et al
   A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer.
   Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-1763.
   PubMed     Abstract available
   
   
   
6. GARG V, Oza AM
   Precision Endocrine Therapy in Endometrial Cancer: Has its time finally come?
   Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3905.
   PubMed     Abstract available
   
   
   
7. BANERJEE S, Ghisoni E, Wolfer A, Ottevanger PB, et al
   Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study.
   Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3368.
   PubMed     Abstract available
   
   
   
8. EERKENS AL, Esajas MD, Brummel K, Vledder A, et al
   Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial.
   Clin Cancer Res. 2025;31:1016-1026.
   PubMed     Abstract available
   
   
   
9. PARK J, Joung JG, Lim MC, Lee J, et al
   Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.
   Clin Cancer Res. 2025 Mar 5. doi: 10.1158/1078-0432.CCR-24-3753.
   PubMed     Abstract available
   
   
   February 2025
10. MICHAELI O, Kim SY, Mitchell SG, Jongmans MCJ, et al
    Update on Cancer Screening in Children with Syndromes of Bone Lesions, Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome, and Other Rare Syndromes.
    Clin Cancer Res. 2025;31:457-465.
    PubMed     Abstract available
    
    
    January 2025
11. ALQAISI HA, Cohn DE, Chern JY, Duska LR, et al
    Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI trial).
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3128.
    PubMed     Abstract available
    
    
    
12. CHAE YK, Corthell L, Patel SP, Edwards R, et al
    A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers.
    Clin Cancer Res. 2025;31:308-315.
    PubMed     Abstract available
    
    
    December 2024
13. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    PubMed     Abstract available
    
    
    
14. SEO A, Xiao W, Gjyshi O, Yoshida-Court K, et al
    Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation.
    Clin Cancer Res. 2024 Dec 16. doi: 10.1158/1078-0432.CCR-24-2343.
    PubMed     Abstract available
    
    
    November 2024
15. GREEN AK, Zhou Q, Iasonos A, Zammarrelli WA, et al
    A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
    Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999.
    PubMed     Abstract available
    
    
    October 2024
16. BRAVO MELGAR J, Laoui D
    Chemotherapy Sparks Tertiary Lymphoid Structures in Metastatic Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-2738.
    PubMed     Abstract available
    
    
    
17. CHAE YK, Othus M, Patel SP, Wilkinson KJ, et al
    SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-0606.
    PubMed     Abstract available
    
    
    
18. SOBERANIS PINA P, Clemens K, Bubie A, Grant B, et al
    Genomic landscape of circulating tumor DNA and real-world outcomes in advanced endometrial cancer.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-2105.
    PubMed     Abstract available
    
    
    September 2024
19. JEON SH, You G, Park J, Chung Y, et al
    Anti-4-1BBxPDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Clin Cancer Res. 2024;30:4155-4166.
    PubMed     Abstract available
    
    
    
20. JOHANNET P, Friedman CF
    The intrauterine device: how to deploy this strategy in the molecular world?
    Clin Cancer Res. 2024 Sep 10. doi: 10.1158/1078-0432.CCR-24-2034.
    PubMed     Abstract available
    
    
    August 2024
21. LANICKOVA T, Hensler M, Kasikova L, Vosahlikova S, et al
    Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
    Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1594.
    PubMed     Abstract available
    
    
    
22. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2024;30:3640.
    PubMed    
    
    
    
23. BLANC-DURAND F, Ngoi NYL, Lim DG, Tan DSP, et al
    Unveiling Commonalities: Exploring Shared Characteristics in Clear Cell Carcinomas of the Gynecologic Tract.
    Clin Cancer Res. 2024 Aug 14. doi: 10.1158/1078-0432.CCR-24-1205.
    PubMed     Abstract available
    
    
    July 2024
24. RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al
    Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice.
    Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-1225.
    PubMed     Abstract available
    
    
    
25. BONFILL-TEIXIDOR E, Neva-Alejo A, Arias A, Cuartas I, et al
    Cervical Cancer Evades the Host Immune System Through the Inhibition of Type I Interferon and CXCL9 by LIF.
    Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-0385.
    PubMed     Abstract available
    
    
    
26. CORTES JE, Abruzzese E, Cardonick EH, Hernandez-Diaz S, et al
    Perspectives on drug development for the treatment of chronic myeloid leukemia in pregnant patients and patients who are breastfeeding.
    Clin Cancer Res. 2024 Jul 5. doi: 10.1158/1078-0432.CCR-24-0826.
    PubMed     Abstract available
    
    
    June 2024
27. BOWEN MB, Melendez B, Zhang Q, Yang RK, et al
    Long-term follow-up of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer reveals relapse characterized by immune exhaustion.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0362.
    PubMed     Abstract available
    
    
    
28. LEE HHY, Chow KL, Wong HS, Chong TY, et al
    Inhibition of aberrantly overexpressed Polo-like kinase 4 is a potential effective treatment for DNA damage repair-deficient uterine leiomyosarcoma.
    Clin Cancer Res. 2024 Jun 7. doi: 10.1158/1078-0432.CCR-23-3720.
    PubMed     Abstract available
    
    
    
29. SANER FAM, Takahashi K, Budden T, Pandey A, et al
    Concurrent RB1 Loss and BRCA-Deficiency Predicts Enhanced Immunological Response and Long-Term Survival in Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-3552.
    PubMed     Abstract available
    
    
    May 2024
30. CORBAUX P, Freyer G, Glehen O, You B, et al
    Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
    Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-24-0507.
    PubMed     Abstract available
    
    
    
31. HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al
    Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.
    Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341.
    PubMed     Abstract available
    
    
    
32. SHETH SS, Oh JE, Bellone S, Siegel ER, et al
    Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
    Clin Cancer Res. 2024;30:1768-1777.
    PubMed     Abstract available
    
    
    
33. KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al
    Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Clin Cancer Res. 2024;30:1906-1915.
    PubMed     Abstract available
    
    
    
34. MIZUMOTO Y, Kyo S, Kiyono T, Takakura M, et al
    Editor's Note: Activation of NF-kappaB Is a Novel Target of KRAS-induced Endometrial Carcinogenesis.
    Clin Cancer Res. 2024;30:1995.
    PubMed    
    
    
    April 2024
35. LORENTZEN GM, Laniewski P, Cui H, Mahnert ND, et al
    Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification.
    Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2934.
    PubMed     Abstract available
    
    
    
36. SON J, Zhang Y, Lin H, Mirallas O, et al
    Clinical and genomic landscape of RAS mutations in gynecologic cancers.
    Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2819.
    PubMed     Abstract available
    
    
    
37. SIVARS L, Jylha C, Crona Guterstam Y, Zupancic M, et al
    Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3941.
    PubMed     Abstract available
    
    
    
38. NIEF CA, Hammer PM, Wang A, Charu V, et al
    Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3158.
    PubMed     Abstract available
    
    
    
39. YANIZ-GALENDE E, Zeng Q, Grau-Bejar JF, Klein C, et al
    Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3836.
    PubMed     Abstract available
    
    
    
40. CHAMBERS L, Haight P, Chalif J, Mehra Y, et al
    Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research.
    Clin Cancer Res. 2024 Apr 25. doi: 10.1158/1078-0432.CCR-23-2570.
    PubMed     Abstract available
    
    
    
41. VENEZIANI AC, Sneha S, Oza AM
    Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
    Clin Cancer Res. 2024;30:1434-1437.
    PubMed     Abstract available
    
    
    
42. GITTO SB, Whicker M, Davies G, Kumar S, et al
    A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
    Clin Cancer Res. 2024;30:1567-1581.
    PubMed     Abstract available
    
    
    March 2024
43. JAMIESON A, Sobral de Barros J, Cochrane DR, Douglas JM, et al
    Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3689.
    PubMed     Abstract available
    
    
    
44. KALOGERA E, Nevala WK, Finnes HD, Suman VJ, et al
    A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
    Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3196.
    PubMed     Abstract available
    
    
    
45. DERMAWAN JK, Chiang S, Singer S, Jadeja B, et al
    Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
    Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-24-0148.
    PubMed     Abstract available
    
    
    January 2024
46. TAN TJ, Sammons S, Im YH, She L, et al
    Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-2513.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.